Danaher Co. (DHR) Shares Bought by Legacy Private Trust Co.

Legacy Private Trust Co. boosted its position in shares of Danaher Co. (NYSE:DHR) by 273.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,624 shares of the conglomerate’s stock after acquiring an additional 24,615 shares during the period. Legacy Private Trust Co.’s holdings in Danaher were worth $3,121,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. GQG Partners LLC acquired a new position in shares of Danaher during the second quarter valued at about $101,000. Zions Bancorporation raised its position in shares of Danaher by 118.3% during the third quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock valued at $106,000 after buying an additional 667 shares during the last quarter. Patten Group Inc. raised its position in shares of Danaher by 262.3% during the third quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock valued at $114,000 after buying an additional 3,497 shares during the last quarter. Monetary Management Group Inc. raised its position in shares of Danaher by 10.7% during the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock valued at $131,000 after buying an additional 150 shares during the last quarter. Finally, Acrospire Investment Management LLC raised its position in shares of Danaher by 185.5% during the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock valued at $143,000 after buying an additional 1,100 shares during the last quarter. 76.11% of the stock is owned by hedge funds and other institutional investors.

Shares of Danaher Co. (DHR) opened at $99.47 on Wednesday. The firm has a market cap of $69,136.20, a PE ratio of 29.34, a P/E/G ratio of 2.15 and a beta of 1.02. Danaher Co. has a 52 week low of $78.97 and a 52 week high of $100.27. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.00.

Danaher (NYSE:DHR) last posted its earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.95 by $0.05. The business had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.47 billion. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.87 earnings per share. equities analysts expect that Danaher Co. will post 3.99 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be paid a $0.14 dividend. The ex-dividend date is Thursday, December 28th. This represents a $0.56 dividend on an annualized basis and a yield of 0.56%. Danaher’s payout ratio is currently 16.52%.

A number of research analysts have recently commented on DHR shares. Morgan Stanley upped their price objective on shares of Danaher from $95.00 to $98.00 and gave the company an “overweight” rating in a research report on Friday, October 20th. Credit Suisse Group upped their price objective on shares of Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a research report on Friday, October 20th. Zacks Investment Research raised shares of Danaher from a “hold” rating to a “buy” rating and set a $97.00 price objective for the company in a research report on Thursday, October 5th. Goldman Sachs Group reaffirmed a “neutral” rating and set a $83.00 price objective on shares of Danaher in a research report on Tuesday, September 26th. Finally, Citigroup upped their price objective on shares of Danaher to $107.00 and gave the company a “buy” rating in a research report on Friday, December 15th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $94.91.

In other Danaher news, SVP Daniel Raskas sold 37,870 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Donald J. Ehrlich sold 10,578 shares of the company’s stock in a transaction dated Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total transaction of $960,693.96. Following the sale, the director now directly owns 104,621 shares in the company, valued at $9,501,679.22. The disclosure for this sale can be found here. In the last three months, insiders sold 273,810 shares of company stock worth $25,218,813. 12.20% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/17/danaher-co-dhr-shares-bought-by-legacy-private-trust-co.html.

Danaher Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply